This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher (TMO) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for AMETEK (AME) This Earnings Season?
by Zacks Equity Research
AMETEK's (AME) Q2 earnings are likely to be driven by strong organic growth and contributions from acquisitions. Yet, ongoing trade tensions might affect its upcoming results.
What's in the Cards for Expedia Group's (EXPE) Q2 Earnings?
by Zacks Equity Research
Strength across segments is likely to drive Expedia Group's (EXPE) second-quarter revenues.
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, McDonald's, Canadian National and NextEra
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, McDonald's, Canadian National and NextEra
Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance
by Zacks Equity Research
Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.
Thermo Fisher Scientific (TMO) Beats Q2 Earnings Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.00% and -0.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?
by Zacks Equity Research
Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.
Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?
by Zacks Equity Research
With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.
Why Earnings Season Could Be Great for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Corporate Giants Set to Win Big on Q2 Earnings This Week
by Nalak Das
Second-quarter 2019 earnings results so far are not as disappointing as expected initially. However, the forecast of overall earnings dip for two consecutive quarters is still looming large.
What to Expect From Cypress Semiconductor's (CY) Q2 Earnings
by Zacks Equity Research
Cypress Semiconductor's (CY) Q2 earnings are likely to be driven by growth in automotive, IoT & USB-C solutions. Yet, ongoing trade tensions & weak macro environment might affect its upcoming results.
Fortive (FTV) Gears Up for Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Fortive's (FTV) second-quarter results are likely to benefit from strong product portfolio and healthy contribution from acquisitions. However, end-market cyclicality might impact its earnings.
Atlassian (TEAM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Atlassian's (TEAM) Q4 results are likely to benefit from strong growth in subscription revenues.
Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.
These $100B+ Stocks are Must-Buys Ahead of Q2 Earnings
by Swarup Gupta
Several sector bellwethers are projected to outperform their earnings estimates this week.
What's in Store for STMicroelectronics' (STM) Q2 Earnings?
by Zacks Equity Research
STMicroelectronics' (STM) Q2 results are likely to gain from robust products & solid execution. Uncertainty in some of the end-markets served and the ongoing U.S.-China trade war pose serious threats.
What's in the Offing for Alphabet's (GOOGL) Q2 Earnings?
by Zacks Equity Research
Alphabet's (GOOGL) focus on artificial intelligence and cloud is likely to boost second-quarter results. However, higher expenses and litigation charges are headwinds.
Analytical Instruments to Aid Thermo Fisher (TMO) Q2 Earnings?
by Zacks Equity Research
Solid global demand, substantial impact from the electron microscopy business and robust volume growth and productivity are likely to favor Thermo Fisher's (TMO) analytical instruments revenues.
PayPal (PYPL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
PayPal's (PYPL) second-quarter results are likely to benefit from strong product portfolio and strategic partnerships.
ASGN to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
ASGN's second-quarter results are likely to be perked up by broad-based segmental growth.
F5 Networks (FFIV) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Growth in software solutions is likely to aid F5 Networks' (FFIV) third-quarter fiscal 2019 results. However, slowdown in systems business is a persistent downside.
TE Connectivity (TEL) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
TE Connectivity's (TEL) industrial and communications solutions portfolio is likely to aid fiscal Q3 results. Yet, weak market conditions in China & softness in European Auto may mar top-line growth.
Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.
IVD Market Sustains Momentum: 3 Stocks in Focus
by Trina Mukherjee
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
Can Product Strength Aid Texas Instruments (TXN) Q2 Earnings?
by Zacks Equity Research
We do not expect Texas Instruments (TXN) to perform well in Q2 owing to weakness in demand and an uncertain macro environment. However, strength in analog & embedded markets might aid results.